Indeed, in CIRT (Cardiovascular Inflammation Reduction Trial), patients with stable CAD and T2DM or metabolic syndrome independent from CRP levels at baseline were included, while in the CANTOS (Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease) trial, patients with elevated residual inflammatory risk with persistently high levels of hsCRP (≥2 mg/L) were included [38]. This evidence concerns the gene CRP and coronary artery disorder.